<DOC>
	<DOC>NCT01508026</DOC>
	<brief_summary>To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.</brief_summary>
	<brief_title>Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male or female outpatients of age 18 years or above Patients diagnosed with stage 1 or stage 2 essential hypertension Normal physical examination findings, electrocardiogram (ECG) results and chest xray; or abnormal findings judged by the Investigator to be not clinically significant Secondary hypertension or severe hypertension Clinically significant cardiovascular disease or heart failure Clinical significant respiratory disease that would prohibit the use of a beta blocker A medical contraindication to discontinuing a current antihypertensive therapy History of Type 1 diabetes mellitus History of Severe Mental Illness except mild depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Stage 1</keyword>
	<keyword>Stage 2</keyword>
	<keyword>Hypertension</keyword>
</DOC>